CD19 and neoplasm: Notably, blinatumomab was toxic to WT tumor cells only, whereas TriBAFF/CD3/ABDCon exhibited consistent toxicity to both WT and CD19-KO tumor cells, a conclusion further substantiated by the cytokine release data (Fig. S12A and S12B).